CXCR4 Antagonists for Wound Healing and Re-Epithelialization
    21.
    发明申请
    CXCR4 Antagonists for Wound Healing and Re-Epithelialization 有权
    CXCR4用于伤口愈合和再上皮化的拮抗剂

    公开(公告)号:US20100055088A1

    公开(公告)日:2010-03-04

    申请号:US11915428

    申请日:2006-05-21

    摘要: The present invention provides novel uses for CXCR4 antagonists, including specifically peptides of the T-140 family, in the treatment of skin burns and other injuries. The invention further provides methods for increasing epithelialisation in a subject in need thereof, and for preventing or inhibiting fibrosis and excessive scar formation, using peptide inhibitors of the T-140 family as well as other CXCR4 antagonists.

    摘要翻译: 本发明提供了用于治疗皮肤灼伤和其他损伤的CXCR4拮抗剂的新用途,特别是包括T-140家族的肽。 本发明进一步提供了使用T-140家族的肽抑制剂以及其它CXCR4拮抗剂来增加有需要的受试者中上皮形成以及用于预防或抑制纤维化和过度瘢痕形成的方法。

    Hematopoietic cell composition for use in transplantation
    22.
    发明授权
    Hematopoietic cell composition for use in transplantation 失效
    用于移植的造血细胞组成

    公开(公告)号:US07101708B1

    公开(公告)日:2006-09-05

    申请号:US09744654

    申请日:1999-07-20

    IPC分类号: C12N5/08 C12N5/02 A61K48/00

    摘要: Cell compositions consisting essentially of mammalian hematopoietic CXCR4+ stem and progenitor capable to migrate in response to stromal-derived factor 1 (SDF-1) and/or capable to adhere to stromal cells in response to an adhesion-inducing agent, are provided for clinical transplantation. Hematopoietic CXCR4−/low stem and progenitor cells can be converted into CXCR4+ cells by stimulation with a suitable agent. The composition consists preferably of human CD38−/low CXCR44 cells.

    摘要翻译: 基本上由哺乳动物造血CXCR4 +干细胞组成的细胞组合物和能够响应于基质衍生因子1(SDF-1)迁移的和/或能够响应于粘附因子1粘附于基质细胞的祖细胞) 诱导剂,用于临床移植。 通过用合适的药剂刺激,可以将造血CXCR4 / /低级干细胞和祖细胞转化成CXCR4 +细胞。 组合物优选由人CD38 - /低CXCR4 4细胞组成。